Payment overview · 2025
General Payments
$365.82
20 reported records · 13 companies
Healthcare provider profile · identity verified
Warren Grady Stumbo, MD
Allopathic & Osteopathic Physicians|Family Medicine · HINDMAN, KY · NPI 1336274596
Verified facts
What the public records show
CMS Open Payments records show Warren Grady Stumbo, MD received $365.82 in general payments during 2025 across 20 reported records.
Novartis Pharmaceuticals Corporation accounted for 16.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Kerendia, Mounjaro, Trelegy Ellipta, Verquvo.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 274 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Verquvo by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 569 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $60.44 | 16.5% | 3 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $42.49 | 11.6% | 2 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.45 | 11.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $39.74 | 10.9% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $34.00 | 9.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $28.56 | 7.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.65 | 5.6% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $18.92 | 5.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.91 | 4.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.42 | 4.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.78 | 4.0% | 1 | 2025 |
| EVOKE PHARMA, INC. | Unresolved — no canonical attribution shown | $14.29 | 3.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.17 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $365.82 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $60.44 | 3 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $42.49 | 2 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $42.45 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $39.74 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $34.00 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $28.56 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $28.56 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.65 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $18.92 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $17.42 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| GIMOTI Normalized: gimoti |
Drug | EVOKE PHARMA, INC. | $14.29 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.17 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 569 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 82 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
274 | 38 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
82 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
82 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
140 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
569 | 63 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1432 | 240 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1079 | 169 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1010 | 166 |
| Lisinopril | Lisinopril | 837 | 162 |
| Gabapentin | Gabapentin | 817 | 138 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 705 | 153 |
| Omeprazole | Omeprazole | 667 | 110 |
| Metoprolol Tartrate | Metoprolol Tartrate | 622 | 118 |
| Amlodipine Besylate | Amlodipine Besylate | 607 | 108 |
| Tamsulosin Hcl | Tamsulosin Hcl | 578 | 89 |
| Eliquis | Apixaban | 569 | 63 |
| Metformin Hcl | Metformin Hcl | 569 | 107 |
| Metoprolol Succinate | Metoprolol Succinate | 542 | 71 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 512 | 102 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 503 | 80 |
| Hydrochlorothiazide | Hydrochlorothiazide | 493 | 89 |
| Furosemide | Furosemide | 479 | 99 |
| Potassium Chloride | Potassium Chloride | 476 | 81 |
| Losartan Potassium | Losartan Potassium | 467 | 88 |
| Clopidogrel | Clopidogrel Bisulfate | 462 | 74 |
| Famotidine | Famotidine | 420 | 74 |
| Allopurinol | Allopurinol | 395 | 63 |
| Simvastatin | Simvastatin | 388 | 63 |
| Clonazepam | Clonazepam | 386 | 62 |
| Montelukast Sodium | Montelukast Sodium | 343 | 51 |
| Tramadol Hcl | Tramadol Hcl | 328 | 72 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 318 | 55 |
| Sertraline Hcl | Sertraline Hcl | 304 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 299 | 60 |
| Trazodone Hcl | Trazodone Hcl | 297 | 43 |
| Buspirone Hcl | Buspirone Hcl | 284 | 47 |
| Farxiga | Dapagliflozin Propanediol | 274 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 270 | 67 |
| Amiodarone Hcl | Amiodarone Hcl | 259 | 48 |
| Hydralazine Hcl | Hydralazine Hcl | 255 | 55 |
| Glipizide | Glipizide | 237 | 47 |
| Bumetanide | Bumetanide | 214 | 31 |
| Donepezil Hcl | Donepezil Hcl | 214 | 28 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 191 | 28 |
| Spironolactone | Spironolactone | 181 | 29 |
| Meloxicam | Meloxicam | 170 | 32 |
| Finasteride | Finasteride | 169 | 25 |
| Carvedilol | Carvedilol | 167 | 36 |
| Levetiracetam | Levetiracetam | 161 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 152 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 148 | 26 |
| Paroxetine Hcl | Paroxetine Hcl | 145 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 141 | 17 |
| Entresto | Sacubitril/Valsartan | 140 | 20 |
| Diazepam | Diazepam | 139 | 24 |
| Memantine Hcl | Memantine Hcl | 136 | 19 |
| Alprazolam | Alprazolam | 135 | 21 |
| Naproxen | Naproxen | 135 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 132 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 130 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 128 | 36 |
| Dicyclomine Hcl | Dicyclomine Hcl | 126 | 30 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 126 | 15 |
| Cilostazol | Cilostazol | 125 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 123 | 31 |
| Diltiazem Hcl | Diltiazem Hcl | 117 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 113 | 26 |
| Ibuprofen | Ibuprofen | 111 | 25 |
| Mirtazapine | Mirtazapine | 110 | 18 |
| Ipratropium Bromide | Ipratropium Bromide | 109 | 32 |
| Xarelto | Rivaroxaban | 104 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 103 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 101 | 15 |
| Latanoprost | Latanoprost | 101 | 17 |
| Valsartan | Valsartan | 101 | 13 |
| Atenolol | Atenolol | 98 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 98 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 97 | 19 |
| Fenofibrate | Fenofibrate | 97 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 95 | 24 |
| Nitroglycerin | Nitroglycerin | 95 | 26 |
| Sucralfate | Sucralfate | 92 | 24 |
| Pregabalin | Pregabalin | 91 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 90 | 21 |
| Linzess | Linaclotide | 89 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 87 | 55 |
| Ezetimibe | Ezetimibe | 86 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 85 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 85 | 18 |
| Jardiance | Empagliflozin | 82 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 81 | 12 |
| Ozempic | Semaglutide | 79 | 12 |
| Methotrexate | Methotrexate Sodium | 75 | 14 |
| Divalproex Sodium | Divalproex Sodium | 74 | 12 |
| Glyxambi | Empagliflozin/Linagliptin | 74 | 11 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 74 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 72 | 11 |
| Ranolazine Er | Ranolazine | 72 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 72 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 70 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 69 | suppressed |
| Baclofen | Baclofen | 67 | 12 |
| Ketoconazole | Ketoconazole | 66 | 14 |
| Olanzapine | Olanzapine | 66 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 65 | 17 |
| Constulose | Lactulose | 64 | 23 |
| Risperidone | Risperidone | 62 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 60 | 11 |
| Phenobarbital | Phenobarbital | 60 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 58 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 58 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 57 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 57 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 57 | suppressed |
| Prednisone | Prednisone | 56 | 37 |
| Xifaxan | Rifaximin | 56 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 55 | suppressed |
| Aripiprazole | Aripiprazole | 53 | suppressed |
| Lansoprazole | Lansoprazole | 53 | suppressed |
| Primidone | Primidone | 53 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 52 | suppressed |
| Haloperidol | Haloperidol | 52 | suppressed |
| Topiramate | Topiramate | 52 | suppressed |
| Fluconazole | Fluconazole | 51 | 27 |
| Synthroid | Levothyroxine Sodium | 51 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 50 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 50 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 49 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 48 | 14 |
| Tradjenta | Linagliptin | 48 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 47 | suppressed |
| Celecoxib | Celecoxib | 47 | 16 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 47 | suppressed |
| Nystatin | Nystatin | 47 | 11 |
| Repatha Sureclick | Evolocumab | 47 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 47 | 31 |
| Hydrocortisone | Hydrocortisone | 45 | 14 |
| Lactulose | Lactulose | 44 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 44 | 11 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 44 | suppressed |
| Chlorthalidone | Chlorthalidone | 43 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 43 | suppressed |
| Gemfibrozil | Gemfibrozil | 43 | suppressed |
| Roflumilast | Roflumilast | 43 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 41 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 41 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 40 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 40 | suppressed |
| Lovastatin | Lovastatin | 39 | suppressed |
| Lorazepam | Lorazepam | 38 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 37 | 11 |
| Metformin Hcl Er | Metformin Hcl | 37 | suppressed |
| Ondansetron Odt | Ondansetron | 37 | 21 |
| Cholestyramine | Cholestyramine (With Sugar) | 36 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 36 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 35 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 34 | suppressed |
| Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | 15 |
| Metoclopramide Hcl | Metoclopramide Hcl | 33 | suppressed |
| Novolin R | Insulin Regular, Human | 33 | suppressed |
| Myrbetriq | Mirabegron | 32 | suppressed |
| Irbesartan | Irbesartan | 31 | suppressed |
| Metolazone | Metolazone | 31 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 31 | suppressed |
| Nystop | Nystatin | 31 | 18 |
| Sevelamer Carbonate | Sevelamer Carbonate | 31 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 30 | suppressed |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 29 | suppressed |
| Sulfasalazine Dr | Sulfasalazine | 29 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 28 | suppressed |
| Dutasteride | Dutasteride | 28 | suppressed |
| Febuxostat | Febuxostat | 28 | suppressed |
| Phenytoin | Phenytoin | 28 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 28 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 28 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 25 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 24 | suppressed |
| Sulfasalazine | Sulfasalazine | 24 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 23 | suppressed |
| Carbamazepine | Carbamazepine | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Azithromycin | Azithromycin | 21 | 21 |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 21 | 21 |
| Invega Sustenna | Paliperidone Palmitate | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | 11 |
| Nabumetone | Nabumetone | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | 12 |
| Novolog | Insulin Aspart | 21 | suppressed |
| Restasis | Cyclosporine | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Kerendia | Finerenone | 20 | suppressed |
| Methimazole | Methimazole | 20 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 17 |
| Loperamide | Loperamide Hcl | 19 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 18 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Glyburide | Glyburide | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 18 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 18 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 17 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Cholestyramine Light | Cholestyramine | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 15 |
| Nyamyc | Nystatin | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 16 | suppressed |
| Rexulti | Brexpiprazole | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Pimozide | Pimozide | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 14 | 12 |
| Combigan | Brimonidine Tartrate/Timolol | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 13 | suppressed |
| Entecavir | Entecavir | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 13 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | 12 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Paliperidone Er | Paliperidone | 12 | suppressed |
| Praluent Pen | Alirocumab | 12 | suppressed |
| Viberzi | Eluxadoline | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 11 | suppressed |
| Scopolamine | Scopolamine | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Verquvo | Vericiguat | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $365.82 · 20 records | Novartis Pharmaceuticals Corporation | AIRSUPRA, CAPLYTA, ELIQUIS, GIMOTI, JARDIANCE, JOURNAVX, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, PYRUKYND, REPATHA, TRELEGY ELLIPTA, VERQUVO, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error